Vasoactive Intestinal Peptide Tumor Global Market Report 2025
상품코드:1751159
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
혈관활성 장 펩타이드 종양 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 연평균 6.3%의 CAGR로 20억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 화학요법에 대한 수요 증가, 약물 승인 가속화, 경구용 약물에 대한 선호도 증가, 질병에 대한 인식 증가, 종양 유병률 증가 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 표적 치료의 발전, 진단 기술 향상, 혁신적 치료법 개발, 맞춤형 의료의 부상, 새로운 치료 솔루션 출시 등을 들 수 있습니다.
표적 치료의 채택 확대는 혈관활성 장 펩타이드(VIP) 종양 시장의 성장을 견인할 것으로 예상됩니다. 표적 치료는 질병, 특히 암의 발생과 진행에 관여하는 특정 분자나 경로에 작용하도록 설계되어 건강한 세포를 보존하면서 비정상적인 세포를 선택적으로 제거할 수 있습니다. 이러한 표적 치료의 증가는 특정 유전자 변이를 표적으로 삼고 부작용을 최소화하여 치료 효과를 향상시키는 정밀 의학의 발전으로 촉진되고 있으며, VIP 종양의 경우 표적 치료는 종양의 성장과 호르몬 분비에 관여하는 중요한 경로를 억제하여 효과를 발휘합니다. 이를 통해 VIP 수치를 낮추고, 심한 설사 등의 증상을 완화하며, 질병의 진행을 늦출 수 있습니다. 예를 들어, 2024년 7월 미국 유전자세포 치료학회(ASGCT)는 2024년 2분기에 76건의 유전자 치료 임상시험이 시작되어 전분기 대비 25% 증가했다고 보고했습니다. 이처럼 표적 치료제의 이용 확대가 VIP 종양 시장 확대에 박차를 가하고 있습니다.
신경내분비종양 유병률의 증가는 혈관활성 장 펩타이드 종양 시장을 견인할 것으로 예상됩니다. 신경내분비종양(NET)은 신경과 호르몬을 생산하는 두 가지 기능을 모두 가진 세포에서 발생하는 희귀한 후발성 암입니다. 이환율의 증가는 진단 방법의 발전으로 이전에는 과소 진단되었던 종양을 더 일찍, 더 정확하게 식별할 수 있게 되었기 때문이며, NET의 희귀한 하위 집합인 VIP 종양은 VIP의 과다 분비가 특징이며, 심한 수양성 설사와 전해질 균형 장애를 유발합니다. 예를 들어, 정부 기관인 Cancer Australia가 2024년 9월에 발표한 바에 따르면, 85세까지 신경내분비종양으로 진단받을 평생 위험은 약 55명 중 1명, 즉 1.8%를 기록할 것으로 예상됩니다. 이 위험은 여성(58명 중 1명, 1.7%)에 비해 남성(52명 중 1명, 1.9%)이 약간 더 높습니다. 따라서 신경내분비종양 발생률의 증가는 VIP 종양 시장의 성장에 기여하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 혈관활성 장 펩타이드 종양 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 혈관활성 장 펩타이드 종양 시장 : 성장률 분석
세계의 혈관활성 장 펩타이드 종양 시장 실적 : 규모와 성장, 2019-2024
세계의 혈관활성 장 펩타이드 종양 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 혈관활성 장 펩타이드 종양 전체 시장(TAM)
제6장 시장 세분화
세계의 혈관활성 장 펩타이드 종양 시장 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
외과적 개입
방사선 치료
화학요법
표적요법
세계의 혈관활성 장 펩타이드 종양 시장 진단별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
영상 기술
생검
초음파 내시경 검사
세계의 혈관활성 장 펩타이드 종양 시장 치료 접근 방식별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
완화의료
치료적 치료
보조 치료
세계의 혈관활성 장 펩타이드 종양 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
암전문 클리닉
진단 검사실
세계의 혈관활성 장 펩타이드 종양 시장, 외과적 개입 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
종양 절제
감량 수술
최소침습 수술
세계의 혈관활성 장 펩타이드 종양 시장 방사선 치료 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
외부 방사선 치료(EBRT)
정위방사선 치료(SBRT)
양성자 치료
세계의 혈관활성 장 펩타이드 종양 시장 화학요법 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세포 상해성 화학요법
병용 화학요법
수술 후 화학요법과 수술 전 화학요법
세계의 혈관활성 장 펩타이드 종양 시장 표적요법 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
소마토스타틴 유사체 요법
티로신 키나아제 억제제(TKI)
단클론항체
제7장 지역별·국가별 분석
세계의 혈관활성 장 펩타이드 종양 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 혈관활성 장 펩타이드 종양 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
혈관활성 장 펩타이드 종양 시장 : 경쟁 구도
혈관활성 장 펩타이드 종양 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
Labcorp Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
Mount Sinai Hospital Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Cleveland Clinic Laboratories
Penn Medicine
Stanford Health Care
UCSF Health
ARUP Laboratories
Dr. Lal PathLabs
Cancer Research UK
Medicover Hospitals
NuView Life Sciences Inc.
DNA Labs India
Inter Science Institute
Ulta Lab Tests
True Health Labs
Ganesh Diagnostic
Agilus Diagnostics
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
혈관활성 장 펩타이드 종양 시장 2029 : 새로운 기회를 제공하는 국가
혈관활성 장 펩타이드 종양 시장 2029 : 새로운 기회를 제공하는 부문
혈관활성 장 펩타이드 종양 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
A vasoactive intestinal peptide (VIP) tumor, also known as a VIPoma, is a rare type of neuroendocrine tumor that most commonly originates in the pancreas. It produces excessive amounts of VIP, resulting in symptoms such as profuse watery diarrhea, dehydration, and electrolyte imbalances. Diagnosis is confirmed through elevated VIP levels in the blood, with treatment options including surgery, medications, and targeted therapies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary treatment approaches for vasoactive intestinal peptide tumors include surgical intervention, radiotherapy, chemotherapy, and targeted therapy. Surgical intervention focuses on safely removing localized tumors, alleviating symptoms, and preventing complications, either through complete or minimally invasive resection. Diagnosis is carried out using various methods such as imaging techniques, biopsy, and endoscopic ultrasound. Therapeutic strategies include palliative care, curative treatment, and adjuvant therapy. These treatments are utilized across a range of end-user settings, including hospitals, cancer specialty clinics, and diagnostic laboratories.
The vasoactive intestinal peptide tumor market research report is one of a series of new reports from The Business Research Company that provides vasoactive intestinal peptide tumor market statistics, including the vasoactive intestinal peptide tumor industry global market size, regional shares, competitors with the vasoactive intestinal peptide tumor market share, detailed vasoactive intestinal peptide tumor market segments, market trends, and opportunities, and any further data you may need to thrive in the vasoactive intestinal peptide tumor industry. This vasoactive intestinal peptide tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The vasoactive intestinal peptide tumor market size has grown strongly in recent years. It will grow from$1.51 billion in 2024 to $1.61 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to the rising prevalence of VIP tumors, increased emphasis on research and development activities, growing healthcare awareness, the expansion of healthcare infrastructure, and enhanced collaborations between biotechnology companies and research institutions.
The vasoactive intestinal peptide tumor market size is expected to see strong growth in the next few years. It will grow to$2.05 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth during the forecast period can be attributed to the rising demand for chemotherapy, accelerated drug approvals, growing preference for oral medications, increased disease awareness, and the increasing prevalence of tumors. Key trends in the forecast period include advancements in targeted therapies, improvements in diagnostic techniques, the development of innovative treatment options, the rise of personalized medicine, and the launch of novel therapeutic solutions.
The increasing adoption of targeted therapy is anticipated to drive the growth of the vasoactive intestinal peptide (VIP) tumor market. Targeted therapies are designed to act on specific molecules or pathways involved in the development and progression of diseases, especially cancer, enabling the selective elimination of abnormal cells while sparing healthy ones. This rise in targeted therapies is fueled by advancements in precision medicine, which improve treatment effectiveness by targeting specific genetic mutations and minimizing adverse effects. In the case of VIP tumors, targeted therapies work by inhibiting critical pathways responsible for tumor growth and hormone secretion. This reduces VIP levels, alleviates symptoms such as intense diarrhea, and slows disease progression. For example, in July 2024, the American Society of Gene and Cell Therapy (ASGCT), a U.S.-based professional organization, reported that 76 gene therapy trials were initiated in the second quarter of 2024, a 25% increase compared to the previous quarter. Thus, the growing use of targeted therapy is fueling the expansion of the VIP tumor market.
The growing prevalence of neuroendocrine tumors is expected to boost the vasoactive intestinal peptide tumor market. Neuroendocrine tumors (NETs) are uncommon, slow-developing cancers originating from cells that have both nerve and hormone-producing functions. Their rising incidence is attributed to advancements in diagnostic methods, which allow for earlier and more precise identification of tumors that were previously underdiagnosed. VIP tumors, a rare subset of NETs, are marked by excessive secretion of VIP, leading to severe watery diarrhea and disturbances in electrolyte balance. For instance, in September 2024 by Cancer Australia, a government agency, the lifetime risk of being diagnosed with neuroendocrine tumors by age 85 is about 1 in 55, or 1.8%. This risk is slightly higher in males (1 in 52 or 1.9%) compared to females (1 in 58 or 1.7%). Therefore, the rising incidence of neuroendocrine tumors is contributing to the growth of the VIP tumor market.
Leading companies in the vasoactive intestinal peptide tumor market are investing in the development of innovative products, including long-acting injectable suspensions, to enhance treatment efficacy, boost patient adherence, and offer prolonged symptom control. These formulations gradually release the active ingredient over time, reducing the frequency of administration. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., a U.S.-based pharmaceutical firm, introduced the first generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the United States. This drug is used for long-term therapy in acromegaly patients who have not responded adequately to surgery or radiation. It also treats severe diarrhea and flushing associated with metastatic carcinoid tumors and VIP-secreting tumors. The launch highlights Teva's capabilities in developing complex generics and supports its strategy of maintaining a solid foothold in the generic drug market.
Major players in the vasoactive intestinal peptide tumor market are Pfizer Inc., Novartis AG, Mayo Clinic, Labcorp Holdings Inc., Mount Sinai Hospital, Cleveland Clinic Laboratories, Penn Medicine, Stanford Health Care, UCSF Health, ARUP Laboratories, Dr. Lal PathLabs, Cancer Research UK, Medicover Hospitals, NuView Life Sciences Inc., DNA Labs India, Inter Science Institute, Ulta Lab Tests, True Health Labs, Ganesh Diagnostic, and Agilus Diagnostics.
North America was the largest region in the vasoactive intestinal peptide tumor market in 2024. The regions covered in vasoactive intestinal peptide tumor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vasoactive intestinal peptide tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vasoactive intestinal peptide tumor market consists of revenues earned by entities by providing services such as genetic testing, immunotherapy, hormone therapy, nuclear medicine, personalized medicine, palliative care, clinical trials, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasoactive intestinal peptide (VIP) Tumor market also includes sales of diagnostic kits, biopsy needles, imaging systems, radiation therapy equipment, chemotherapy drugs, targeted therapy drugs, surgical instruments, and supportive care medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vasoactive Intestinal Peptide Tumor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vasoactive intestinal peptide tumor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for vasoactive intestinal peptide tumor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vasoactive intestinal peptide tumor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Surgical Intervention; Radiotherapy; Chemotherapy; Targeted Therapy
2) By Diagnosis: Imaging Techniques; Biopsy; Endoscopic Ultrasound
3) By Therapeutic Approach: Palliative Care; Curative Treatment; Adjuvant Treatment
4) By End-User: Hospitals; Cancer Specialty Clinics; Diagnostic Laboratories
Subsegments:
1) By Surgical Intervention: Tumor Resection; Debulking Surgery; Minimally Invasive Surgery
2) By Radiotherapy: External Beam Radiation Therapy (EBRT); Stereotactic Body Radiation Therapy (SBRT); Proton Therapy
3) By Chemotherapy: Cytotoxic Chemotherapy; Combination Chemotherapy; Adjuvant And Neoadjuvant Chemotherapy
4) By Targeted Therapy: Somatostatin Analog Therapy; Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies
Companies Mentioned: Pfizer Inc.; Novartis AG; Mayo Clinic; Labcorp Holdings Inc.; Mount Sinai Hospital
3. Vasoactive Intestinal Peptide Tumor Market Trends And Strategies
4. Vasoactive Intestinal Peptide Tumor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Vasoactive Intestinal Peptide Tumor Growth Analysis And Strategic Analysis Framework
5.1. Global Vasoactive Intestinal Peptide Tumor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Vasoactive Intestinal Peptide Tumor Market Growth Rate Analysis
5.4. Global Vasoactive Intestinal Peptide Tumor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Vasoactive Intestinal Peptide Tumor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Vasoactive Intestinal Peptide Tumor Total Addressable Market (TAM)
6.1. Global Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgical Intervention
Radiotherapy
Chemotherapy
Targeted Therapy
6.2. Global Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Imaging Techniques
Biopsy
Endoscopic Ultrasound
6.3. Global Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Palliative Care
Curative Treatment
Adjuvant Treatment
6.4. Global Vasoactive Intestinal Peptide Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Specialty Clinics
Diagnostic Laboratories
6.5. Global Vasoactive Intestinal Peptide Tumor Market, Sub-Segmentation Of Surgical Intervention, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tumor Resection
Debulking Surgery
Minimally Invasive Surgery
6.6. Global Vasoactive Intestinal Peptide Tumor Market, Sub-Segmentation Of Radiotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
External Beam Radiation Therapy (EBRT)
Stereotactic Body Radiation Therapy (SBRT)
Proton Therapy
6.7. Global Vasoactive Intestinal Peptide Tumor Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cytotoxic Chemotherapy
Combination Chemotherapy
Adjuvant And Neoadjuvant Chemotherapy
6.8. Global Vasoactive Intestinal Peptide Tumor Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Somatostatin Analog Therapy
Tyrosine Kinase Inhibitors (TKIs)
Monoclonal Antibodies
7. Vasoactive Intestinal Peptide Tumor Market Regional And Country Analysis
7.1. Global Vasoactive Intestinal Peptide Tumor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Vasoactive Intestinal Peptide Tumor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Vasoactive Intestinal Peptide Tumor Market
9.1. China Vasoactive Intestinal Peptide Tumor Market Overview
9.2. China Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Vasoactive Intestinal Peptide Tumor Market
10.1. India Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Vasoactive Intestinal Peptide Tumor Market
11.1. Japan Vasoactive Intestinal Peptide Tumor Market Overview
11.2. Japan Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Vasoactive Intestinal Peptide Tumor Market
12.1. Australia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Vasoactive Intestinal Peptide Tumor Market
13.1. Indonesia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Vasoactive Intestinal Peptide Tumor Market
14.1. South Korea Vasoactive Intestinal Peptide Tumor Market Overview
14.2. South Korea Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Vasoactive Intestinal Peptide Tumor Market
15.1. Western Europe Vasoactive Intestinal Peptide Tumor Market Overview
15.2. Western Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Vasoactive Intestinal Peptide Tumor Market
16.1. UK Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Vasoactive Intestinal Peptide Tumor Market
21.1. Eastern Europe Vasoactive Intestinal Peptide Tumor Market Overview
21.2. Eastern Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Vasoactive Intestinal Peptide Tumor Market
22.1. Russia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Vasoactive Intestinal Peptide Tumor Market
23.1. North America Vasoactive Intestinal Peptide Tumor Market Overview
23.2. North America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Vasoactive Intestinal Peptide Tumor Market
24.1. USA Vasoactive Intestinal Peptide Tumor Market Overview
24.2. USA Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Vasoactive Intestinal Peptide Tumor Market
26.1. South America Vasoactive Intestinal Peptide Tumor Market Overview
26.2. South America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Vasoactive Intestinal Peptide Tumor Market
27.1. Brazil Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Vasoactive Intestinal Peptide Tumor Market
28.1. Middle East Vasoactive Intestinal Peptide Tumor Market Overview
28.2. Middle East Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Vasoactive Intestinal Peptide Tumor Market
29.1. Africa Vasoactive Intestinal Peptide Tumor Market Overview
29.2. Africa Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Vasoactive Intestinal Peptide Tumor Market Competitive Landscape And Company Profiles
